rhIL-11

PreclinicalSmall molecule

Pfizer

rhIL-11 is one of 47 small molecule programs targeting Immune Thrombocytopenia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Immune ThrombocytopeniaActive, not recruiting

Immune ThrombocytopeniaPreclinical

Active, not recruiting

Competition

Competitive Landscape

54 competitors in Immune Thrombocytopenia

#DrugCompanyPhaseTrials

Promacta

GSK

Approved

14 2

Rituxan

Roche

Approved

13 3

Decadron

AAspen Global Incorporated

Approved

21 4

Plaquenil

Jazz Pharmaceuticals

Approved

1 5

Oncovin

Eli Lilly

Approved

1 6

Rayos

RRoxane Laboratories

Approved

6 7

Imuran

LLegacy Health System

Approved

1 8

Doptelet

AAkarx

Phase 3

6 9

Vyvgart

Argenx

Phase 3

5 10

Nublexa

BBeijing InnoCare Pharma Tech Co., Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Colorectal Cancer1 trial

Comparison of Interleukin-11 and rhTPO for Recurrent Colorectal Cancer Patients With Thrombocytopenia

Unknown status·FFudan University·Phase 2·NCT03823079·50 enrolled

Interleukin1 trial

A Phase Ⅲa Study of Genetically Modified Recombinant Human Interleukin-11

Completed·BBeijing Northland Biotech. Co., Ltd.·Phase 3·NCT01663441·62 enrolled

Immune Thrombocytopenia1 trial

Recombinant Human Interleukin-11 Combination Low-dose Rituximab in Immune Thrombocytopenia

Withdrawn·MMing Hou··NCT01317966

Ulcerative Colitis1 trial

Study Evaluating rhIL-11 in Left-Sided Ulcerative Colitis

Terminated· Pfizer logo

Pfizer·Phase 1·NCT00038922

Thrombocytopenia1 trial

Effect of rhIL-11 in Patients With Thrombocytopenia for Childhood ALL

Completed·SShanghai Children's Medical Center·Phase 4·NCT02314273·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for rhIL-11. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — rhIL-11 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for rhIL-11. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Pfizer

rhIL-11

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Colorectal Cancer1 trial

Interleukin1 trial

Immune Thrombocytopenia1 trial

Ulcerative Colitis1 trial

Thrombocytopenia1 trial

References

Drug Info

Quick Facts

Related News